Literature DB >> 17696681

Abstinence-based incentives in methadone maintenance: interaction with intake stimulant test results.

Maxine L Stitzer1, Jessica Peirce, Nancy M Petry, Kimberly Kirby, John Roll, Joseph Krasnansky, Allan Cohen, Jack Blaine, Ryan Vandrey, Ken Kolodner, Rui Li.   

Abstract

Baseline drug use detected in urine toxicology has been shown to predict drug abuse treatment outcome, including response to contingency management interventions with drug abstinence as their target. This study examined the association between baseline urine test result and treatment outcome in stabilized methadone maintenance patients with ongoing stimulant use to determine whether abstinence incentives were differentially effective in those testing stimulant negative versus positive at study entry. Participants were 386 methadone-maintained patients who took part in a National Drug Abuse Treatment Clinical Trials Network multisite study aimed at reducing stimulant abuse during treatment (J. M. Peirce et al., 2006). At study intake, 24% of participants tested stimulant negative and 76% tested positive. Those testing negative at entry submitted 82% negative urines during the study versus 36% for those testing positive at entry (odds ratio [OR] = 8.67; confidence interval [CI] = 5.81-12.94). Compared with those receiving usual care, the addition of abstinence incentives resulted in a significant increase in stimulant-negative urine samples submitted during the study both for those testing negative at study entry (OR = 2.27; CI = 1.13- 4.75) and for those testing positive (OR = 1.84; CI = 1.25-2.71). These findings suggest that abstinence incentives have significant clinical benefits independent of initial drug use severity among methadone maintenance patients with ongoing stimulant drug use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696681     DOI: 10.1037/1064-1297.15.4.344

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  26 in total

1.  Interdependent group contingency management for cocaine-dependent methadone maintenance patients.

Authors:  Kimberly C Kirby; Marylouise E Kerwin; Carolyn M Carpenedo; Beth J Rosenwasser; Robert S Gardner
Journal:  J Appl Behav Anal       Date:  2008

2.  Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring.

Authors:  Colin Cunningham; Maxine Stitzer; Aimee N C Campbell; Martina Pavlicova; Mei-Chen Hu; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2015-09-21

3.  Substance Abuse Treatment Patients in Housing Programs Respond to Contingency Management Interventions.

Authors:  Carla J Rash; Sheila M Alessi; Nancy M Petry
Journal:  J Subst Abuse Treat       Date:  2016-07-19

4.  Amount of earnings during prize contingency management treatment is associated with posttreatment abstinence outcomes.

Authors:  Nancy M Petry; John M Roll
Journal:  Exp Clin Psychopharmacol       Date:  2011-06-27       Impact factor: 3.157

5.  Considerations for Implementing Contingency Management in Substance Abuse Treatment Clinics: The Veterans Affairs Initiative as a Model.

Authors:  Carla J Rash; Dominick DePhilippis
Journal:  Perspect Behav Sci       Date:  2019-06-26

6.  Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.

Authors:  Kelly E Dunn; Joseph A Harrison; Jeannie-Marie Leoutsakos; Dingfen Han; Eric C Strain
Journal:  Alcohol Alcohol       Date:  2016-08-27       Impact factor: 2.826

7.  Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.

Authors:  Nancy M Petry; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2013-03-25

8.  Randomized clinical trial examining duration of voucher-based reinforcement therapy for cocaine abstinence.

Authors:  Kimberly C Kirby; Carolyn M Carpenedo; Karen L Dugosh; Beth J Rosenwasser; Lois A Benishek; Alicia Janik; Rachel Keashen; Elena Bresani; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2013-05-13       Impact factor: 4.492

9.  A 'missing not at random' (MNAR) and 'missing at random' (MAR) growth model comparison with a buprenorphine/naloxone clinical trial.

Authors:  Sterling McPherson; Celestina Barbosa-Leiker; Mary Rose Mamey; Michael McDonell; Craig K Enders; John Roll
Journal:  Addiction       Date:  2014-10-16       Impact factor: 6.526

10.  Ethnic differences in HIV risk behaviors among methadone-maintained women receiving contingency management for cocaine use disorders.

Authors:  Danielle Barry; Jeremiah Weinstock; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2008-08-06       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.